FierceBiotech22h
Novo Nordisk gets BACH1, inking IMMvention deal to orchestrate attack on sickle cell disease
Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...
ncbiotech.org23h
IMMvention Therapeutix to collaborate with Novo Nordisk on oral therapies for sickle cell, other chronic diseases
IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...
IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...
Frontiers16d
Se-methylselenocysteine inhibits inflammatory response in an LPS-stimulated chicken HD11 macrophage-like cell model through the NFKB2 pathway
Among the various sources of selenium supplementations, the Se-methylselenocysteine (SeMC) is a natural organic selenium compound that has been demonstrated to have multiple advantages in terms of ...
C&EN22d
Multiarm-Assisted Design of Dendron-like Degradable Ionizable Lipids Facilitates Systemic mRNA Delivery to the Spleen
Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, ...
Frontiers9d
MicroRNAs signatures as potential molecular markers in mild cognitive impairment: a meta-analysis
Mild cognitive impairment (MCI) is characterized by a decline in cognitive functioning without significant interference in daily activities. Its high heterogeneity and elevated conversion rate to ...